Igm System News Today

Share: HAUPPAUGE, N.Y., July 20, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembios DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazils Ministry of Health in addressing the COVID-19 pandemic. The DPP SARS-CoV-2 Antigen test is designed to detect the SA...

Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil HAUPPAUGE, N.Y., July 20, 2021 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembio’s DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazil�...

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors HAUPPAUGE, N.Y., Dec. 17, 2020 — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Acheson, M.D. to the Company’s Board of Directors. “We are pleased to welcome David to our Board of Directors. He adds directly applicable expertise i...